Industry News
Pharmaceutical Industry News
Antheia is teaming up with…
Antheia is teaming up with TAPI—Teva’s active pharmaceutical ingredient and contract manufacturing business—in a bid to further commercialize its pipeline of biosynthetic drug ingredients and key start materials.
Novartis expect the expansion in…
Novartis expect the expansion in North Carolina will add 700 new employees to its ranks. The manufacturing campus will span some 700,000 square feet between new and existing space, Novartis said.
Agios’ shares nosedived by 49%…
Agios’ shares nosedived by 49% on Wednesday morning after the company revealed mixed phase 3 results for Pyrukynd in sickle cell disease.
Two months after Celltrion bought…
Two months after Celltrion bought a U.S. manufacturing facility from Eli Lilly for $330 million, the South Korean biosimilar specialist said it will spend another 700 billion won ($478 million) to upgrade the plant.
¿Qué son los ensayos clínicos y cómo funcionan?
Una periodista del New York Times explica qué son, por qué son importantes y cómo nos ayudan a entender mejor la medicina.
Una píldora para la libido femenina se convierte en un momento cultural
Hace una década, Cindy Eckert tenía dificultades para convencer a los escépticos sobre un medicamento para la premenopausia. Últimamente, su negocio está en auge.
Alkermes and Avadel have reached…
Alkermes and Avadel have reached an accord on a new offer that would see Alkermes pay up to $22.50 per Avadel share to acquire the company. Both drugmakers’ boards have blessed the amended deal and
Teva Pharmaceutical is launching…
Teva Pharmaceutical is launching its first global innovation platform, challenging startups to submit novel strategies to tackle seven industry hurdles that run the gamut from manufacturing to R&D.
With a fresh FDA endorsement for…
With a fresh FDA endorsement for its drug plozasiran, Pasadena-based Arrowhead Pharmaceuticals has successfully broken through to the commercial realm.
The bankruptcy reorganization plan…
The bankruptcy reorganization plan will deliver $7.4 billion to creditors, including an up-to-$7 billion contribution from the Sackler family, while Purdue Pharma will dissolve into a new company called Knoa Pharma.
The distinction is important…
The distinction is important because under Avadel's existing transaction agreement with Alkermes, the latter company now has five business days to "discuss or negotiate in good faith" any potential amendments to its prior offer.
Positive results from a…
Positive results from a proof-of-concept study evaluating Merck’s Winrevair pave the way for further study of the activin signaling inhibitor as a potential treatment for a subset of heart failure patients.
Monday, the FDA’s Office of…
Monday, the FDA’s Office of Prescription Drug Promotion posted a new untitled letter dated Sept. 23 and addressed to AstraZeneca.
In a bid to deepen its…
In a bid to deepen its manufacturing foothold in the U.S., Regeneron Pharmaceuticals in April pledged production and infrastructure investments surpassing $7 billion across North Carolina and its native Empire State. Now, more than half
The company will spend…
The company will spend approximately $1.5 billion in capital investments to grow its U.S. plasma-based manufacturing capabilities over the next five years.
Having found success with its Jazz…
Having found success with its Jazz and BeOne-licensed cancer med Ziihera, Zymeworks will apply the commercial and late-stage framework for that drug to all its products going forward. The new licensing-focused model forms part of
Cytokinetics is following in the…
Cytokinetics is following in the footsteps of Bristol Myers Squibb as it prepares to try to wrest control of the heart disease market away from the Big Pharma. About a year after BMS backed an
Biogen has had two years to gear…
Biogen has had two years to gear up for the impending launch of Sandoz's biosimilar Tyruko, which has now hit the U.S. market after earning FDA approval in 2023.
Days after joining its fellow…
Days after joining its fellow GLP-1 giant, Eli Lilly, in coming to agreements with the Trump administration to slash the costs of their uber-popular weight loss meds in the U.S., Novo Nordisk has pulled back
Jazz described the readout as…
Jazz described the readout as boosting its confidence that it has a HER2-targeted "agent-of-choice" for first-line patients with HER2-positive gastroesophageal adenocarcinoma (GEA), including cancers of the stomach, gastroesophageal junction and esophagus.